Cooper T J, Ladusans E, Williams P E, Polychronopoulos V, Gaya H, Rudd R M
J Antimicrob Chemother. 1985 Sep;16(3):373-8. doi: 10.1093/jac/16.3.373.
We assessed oral cefuroxime axetil in an open study of 30 patients with lower respiratory tract infection and then compared oral cefuroxime with oral amoxycillin in a randomized double blind study in a further 40 patients. Satisfactory clinical responses were obtained in 73% of patients receiving cefuroxime axetil 500 mg tid in the open study, and in the comparative study in 71% of patients receiving cefuroxime axetil 500 mg bd, in 60% of patients receiving cefuroxime axetil 500 mg tid and in 63% of patients receiving amoxycillin 500 mg tid. There were no significant differences in response rates between the three regimens in the comparative study. There were no important adverse effects in any of the patients. Oral cefuroxime axetil is safe and effective in the therapy of lower respiratory tract infections.
我们在一项针对30例下呼吸道感染患者的开放性研究中评估了口服头孢呋辛酯，然后在另外40例患者中进行的随机双盲研究中，将口服头孢呋辛与口服阿莫西林进行了比较。在开放性研究中，73%接受500毫克头孢呋辛酯每日三次治疗的患者获得了满意的临床反应；在比较研究中，71%接受500毫克头孢呋辛酯每日两次治疗的患者、60%接受500毫克头孢呋辛酯每日三次治疗的患者以及63%接受500毫克阿莫西林每日三次治疗的患者获得了满意的临床反应。在比较研究中，三种治疗方案的反应率没有显著差异。所有患者均未出现重要不良反应。口服头孢呋辛酯在治疗下呼吸道感染方面安全有效。
